Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3170386 | 0.88 | HSD17B10 (0.60) | MAPTRAB9AMEN1KMT2ANPSR1 | |
| Acetic Acid SCHEMBL6243148 | 0.87 | MAPT (0.61) | MAPTRAB9AMEN1KMT2ANPSR1 | |
| Diphenylamine SCHEMBL6904395 | 0.83 | MAPT (0.71) | MAPTRAB9AMEN1KMT2APOLB | |
| Diphenylamine SCHEMBL28553827 | 0.83 | MAPT (0.71) | MAPTRAB9AMEN1KMT2APOLB | |
| Diphenylamine SCHEMBL374606 | 0.79 | MAPT (0.71) | MAPTRAB9AMEN1KMT2APOLB | |
| Diphenylamine SCHEMBL1626446 | 0.75 | MAPT (0.61) | MAPTMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL7152596 | 0.75 | RAB9A (0.65) | MAPTRAB9AMEN1KMT2ANPSR1 | |
| Diphenylamine SCHEMBL8610102 | 0.74 | MAPT (0.65) | MAPTRAB9AMEN1KMT2APOLB | |
| Diphenylamine SCHEMBL21145296 | 0.74 | MAPT (0.65) | MAPTRAB9AMEN1KMT2APOLB | |
| SCHEMBL12218114 | 0.74 | MEN1 (1.00) | MAPTRAB9AMEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309835-A1 | METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES | REVISION THERAPEUTICS, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120288568-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA SERUM RETINOL, SERUM RETINOL BINDING PROTEIN (RBP), AND/OR SERUM RETINOL-RBP MODULATION | REVISION THERAPEUTICS, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120202885-A1 | METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES | REVISION THERAPEUTICS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| EP-2289500-A1 | Retinol binding protein and transthyretin modulators for treating hypertosis, Alzheimer's disease or idiopathic intracranial hypertension | ReVision Therapeutics, Inc. (US) | 2011-03-02 | — | — | EP | disclosed |
| EP-1904043-A4 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA SERUM RETINOL, SERUM RETINOL BINDING PROTEIN (RBP), AND/OR SERUM RETINOL-RBP MODULATION | SIRION THERAPEUTICS INC (US) | 2008-09-17 | — | — | EP | disclosed |
| EP-1930046-A1 | Retinol binding protein and transthyretin modulators for treating diabetes | Sirion Therapeutics, Inc. (US) | 2008-06-11 | — | — | EP | disclosed |
| EP-1827407-A4 | METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES | SIRION THERAPEUTICS INC (US) | 2008-05-21 | — | — | EP | disclosed |
| EP-1904043-A2 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA SERUM RETINOL, SERUM RETINOL BINDING PROTEIN (RBP), AND/OR SERUM RETINOL-RBP MODULATION | Sirion Therapeutics, Inc. (US) | 2008-04-02 | — | — | EP | disclosed |
| EP-1827407-A2 | METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES | Sirion Therapeutics, Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20070015827-A1 | Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (RBP), and/or serum retinol-RBP modulation | SYTERA, INC. (US) | 2007-01-18 | — | — | US | disclosed |
| WO-2007008821-A2 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA SERUM RETINOL, SERUM RETINOL BINDING PROTEIN (RBP), AND/OR SERUM RETINOL-RBP MODULATION | SIRION THERAPEUTICS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| US-20060135460-A1 | Methods, assays and compositions for treating retinol-related diseases | SYTERA, INC. (US) | 2006-06-22 | — | — | US | disclosed |
| WO-2006063128-A2 | METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES | SIRION THERAPEUTICS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120288568-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA SERUM RETINOL, SERUM RETINOL BINDING PROTEIN (RBP), AND/OR SERUM RETINOL-RBP MODULATION | RBP1, RBP4, ALDH1A2 | MAPT 1143/4885RAB9A 1958/4885MEN1 4677/4885 |
| US-20120309835-A1 | METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES | RBP1, RBP4, TTR | MAPT 223/4885RAB9A 2415/4885MEN1 1658/4885 |
| US-20060135460-A1 | Methods, assays and compositions for treating retinol-related diseases | RBP1, RBP4, TTR | MAPT 223/4885RAB9A 2415/4885MEN1 1658/4885 |
| US-20070015827-A1 | Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (RBP), and/or serum retinol-RBP modulation | RBP1, RBP4, ALDH1A2 | MAPT 1143/4885RAB9A 1958/4885MEN1 4677/4885 |
| US-20120202885-A1 | METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES | RBP1, RBP4, TTR | MAPT 223/4885RAB9A 2415/4885MEN1 1658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.